Forest City Enterprises
SlowingCleveland, OHBiotechnology, Healthcare, PharmaceuticalsLast fund filed March 2021
5 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Forest City Enterprises | March 2021 | $110,000 | $110,000 | 110 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
5 partners are named across this firm’s filings, 5 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Ketan Patel | Slowing | Biotech & pharma, Medical devices, Healthcare services | 12 | 1 |
| Charles Obert | Quiet | None listed | 0 | 0 |
| Christopher Mellis | Quiet | None listed | 0 | 0 |
| Frank Constanzo | Quiet | None listed | 0 | 0 |
| Frank Costanzo | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Forest City Enterprises’s own portfolio companies, based on 12 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Forest City Enterprises’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Venbio Global Strategic | 2 | Menlo Therapeutics, NFlection Therapeutics |
| Vivo Innovation | 2 | Aclaris Therapeutics, Menlo Therapeutics |
| Vivo Ventures VII Affiliates | 2 | Aclaris Therapeutics, Menlo Therapeutics |
| 270 Healthcare Growth | 1 | ABK Biomedical |
| Aisling Capital | 1 | Aclaris Therapeutics |
| Atlas Venture | 1 | Comanche Biopharma |
| Baird Venture Partners | 1 | Amphora Medical |
| Hatteras Venture Partners | 1 | Avivomed |
| New Leaf | 1 | Rallybio Holdings |
| Nexeption Capital | 1 | Aclaris Therapeutics |
| Rivervest | 1 | Avalyn Pharma |
| Sofinnova Venture Partners | 1 | Aclaris Therapeutics |
| Venbio Select | 1 | NFlection Therapeutics |
A shared board seat: a company where filings name a Forest City Enterprises partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.